Skip to content
Study details
Enrolling now

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

Upstream Bio Inc.
NCT IDNCT06981078ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

666

Study length

about 3.1 years

Ages

40–85

Locations

32 sites in CA, CO, FL +9

What this study is about

This trial is testing a treatment called verekitug (UPB-101) in people with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). The goal is to see if this treatment helps improve symptoms and is safe for them.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Verekitug

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Change in pre-bronchodilator forced expiratory capacity in 1 second (FEV1), Incidence of treatment-emergent adverse events and serious adverse events

Body systems

Respiratory